A continuous heparin infusion is to begin at 15 units/kg/hr for a client weighing 82 kg. Available: 25,000 units of heparin in 250 mL D5W. Calculate the mL/hr. (the pump is capable of delivering in tenths of an mL).

A) The healthcare provider's order
While the healthcare provider's order is crucial for ensuring that the correct drug and dosage are administered, it is not something that would be written on the reconstituted drug label. The reconstituted drug label is intended to communicate specific information about the reconstitution process and the product's current status, but the order itself is typically not part of this information.

B) Diluent
When reconstituting a medication, it is essential to note the diluent used. The diluent refers to the liquid used to mix the powdered medication and turn it into a solution or suspension. Including this information on the drug label ensures that anyone handling the medication can verify the proper solution used for reconstitution, which is important for both correct administration and stability of the drug.

C) Date to discard
After a medication has been reconstituted, it often has a limited shelf life, and it is important to write the date to discard on the drug label. This ensures that the medication is used within its recommended time frame to avoid potential degradation or loss of potency. The discard date is especially important in hospitals or clinics where drugs are prepared in advance.

D) Initials
The nurse should always include their initials on the reconstituted drug label. This serves as a means of accountability, allowing others to know who prepared the medication. It also helps ensure proper identification in case of questions or errors regarding the preparation.

A) Patients with hypertension
Low molecular weight heparin (LMWH) is not primarily used to treat hypertension. Hypertension (high blood pressure) is typically managed with antihypertensive medications like ACE inhibitors, beta-blockers, diuretics, or calcium channel blockers. LMWH is an anticoagulant, which works to prevent blood clots rather than controlling blood pressure.

B) Patients with asthma
LMWH is not typically used to treat asthma. Asthma is a chronic respiratory condition that is usually managed with bronchodilators (e.g., albuterol) and anti-inflammatory drugs such as corticosteroids. While patients with asthma may be at risk for blood clots under certain conditions (e.g., severe asthma exacerbations, immobility), LMWH is not a first-line treatment for asthma.

C) Patients with diabetes
While people with diabetes may be at an increased risk of developing blood clots, LMWH is not specifically used to treat diabetes. Diabetes is typically managed with insulin, oral hypoglycemic agents, lifestyle modifications, and other medications to control blood glucose levels. LMWH is an anticoagulant used for conditions that require prevention of clot formation, such as deep vein thrombosis (DVT).

D) Patients with deep vein thrombosis (DVT)
LMWH is commonly prescribed to patients with deep vein thrombosis (DVT). DVT occurs when a blood clot forms in a deep vein, usually in the legs. LMWH is a type of anticoagulant that prevents the formation of further clots by inhibiting factors involved in blood clotting. It is especially effective for patients with DVT or those at high risk for thromboembolic events, such as after surgery or during prolonged immobility. LMWH provides more predictable anticoagulation and requires less frequent monitoring than unfractionated heparin, making it ideal for outpatient management and in hospital settings.